MobiHealth News July 15, 2021
Mallory Hackett

Once combined, the company will operate as HeartFlow Group and will trade on the New York Stock Exchange under the symbol HFLO.

Heartflow, a company that specializes in creating computerized heart models to treat coronary diseases, announced plans to go public through a $2.4 billion merger with Longview Acquisition Corp. II, a special purpose acquisition company (SPAC) sponsored by affiliates of Glenview Capital Management.

Once combined, the company will operate as HeartFlow Group and trade on the New York Stock Exchange under the symbol HFLO.

The deal is expected to bring in $400 million in cash to be used for company growth, product development and other general corporate purposes, according to the announcement.

“The HeartFlow team is dedicated to providing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Investments, Medical Devices, Trends
Related Articles:
Exo adds FDA-cleared AI tools to handheld ultrasound system
FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices
FDA launches initiative to advance home healthcare models, devices
Is Telepathy Possible? Perhaps, Due To New Technology
FDA Proposes Updated Guidance Concerning Cybersecurity of Medical Devices

Share This Article